Subscribe to our newsletter and stay informed

Check out our list of top companies

Check out our carefully compiled lists of the most relevant and impactful companies within their fields.

Check out our list of top unicorns

Read and learn about the biggest companies that various countries have produced, how they made it, and what the future looks like for them.
December 28, 2023

Sentante Secures €6 Million Funding to Revolutionize Endovascular Procedures

Groundbreaking milestone by introducing the world's inaugural robotic teleoperated system for endovascular interventions

In a groundbreaking leap towards transforming endovascular interventions, Lithuanian medical device company Sentante has just sealed a significant €6 million in Seed funding. Spearheaded by Practica Capital, this funding round also boasts the participation of the EIC fund, propelling Sentante into the forefront of medical innovation. The company's revolutionary teleoperated robotic system, poised to redefine cardiovascular treatments, promises not only enhanced precision but also a paradigm shift in the way physicians approach critical procedures.

Every year, over six million endovascular procedures are performed to manage cardiovascular diseases, ranging from strokes to heart attacks and peripheral artery diseases. Astonishingly, despite the market's sheer size and continuous innovation, the approach to these procedures has witnessed minimal evolution over the last four decades. Physicians find themselves navigating catheters and guidewires manually, operating next to X-ray sources while clad in heavy lead aprons. This outdated method poses considerable risks, including medical errors and complications due to an inherently non-ergonomic workspace and prolonged X-ray exposure.

Enter Sentante, the brainchild of UAB Inovatyvi Medicina, offering a transformative solution to these challenges.

Sentante represents an ingenious teleoperated robotic system designed to perform entire endovascular interventions remotely. By eliminating the need for physicians to operate in close proximity to harmful X-ray radiation, Sentante introduces a paradigm shift in safety, precision, and overall procedural excellence. The robotic system seamlessly integrates into existing treatment workflows, utilizing the same medical devices employed in manual procedures.

This groundbreaking technology not only addresses current challenges but also opens doors to a future where endovascular treatments can be conducted from remote locations, eliminating the necessity for physical patient transfer. The potential impact on critical cases, such as strokes, where time plays a pivotal role in patient outcomes, cannot be overstated.

Edvardas Satkauskas, co-founder and CEO of Sentante, expressed gratitude for the support and trust of new investors, emphasizing the technology's potential to revolutionize endovascular procedures. Dr. Tomas Baltrunas, co-founder and Chief Medical Officer, anticipates a significant milestone in 2024 with the initiation of Sentante's first-in-human clinical study. The Sentante robotic system, controlled intuitively via conventional endovascular devices, promises a near-natural haptic force feedback experience, even in remote operation.

Sentante's successful funding round marks the beginning of a transformative journey in cardiovascular interventions. As the company prepares to embark on its first-in-human clinical study, the world eagerly anticipates witnessing Sentante's capabilities unfold. This innovative robotic system is not merely a technological advancement; it symbolizes a leap toward a safer, more precise, and globally accessible future for endovascular procedures.

Neil Hodgson Coyle
Neil Hodgson-Coyle
Editorial chief at TechNews180
Back to top

Related articles

chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram